Browsing Category
Pharma Industry News
4722 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move
AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now.
How next-generation masking strategies could reshape PSMA-directed T cell engager development
How Janux Therapeutics is advancing masked T cell engagers with JANX014. Find out what this means for prostate cancer treatment and immunotherapy.
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Kailera Therapeutics priced its IPO at $16 to raise $625M. Read what the deal means for KLRA, obesity drug competition, and biotech funding now.
Why SK Life Science Labs’ AACR 2026 data could put targeted protein degradation back in the oncology spotlight
SK Life Science Labs unveiled new AACR 2026 preclinical data on p300 and PRMT5 degraders. Read why this oncology strategy could matter next.
Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Why selective immune homeostasis is the bigger story behind CUE-401
Cue Biopharma’s CUE-401 data points to a bigger autoimmune story. Read why selective immune homeostasis could reshape immunology pipelines.
Why eftilagimod alfa’s soft tissue sarcoma data now matters more than ever for Immutep Limited
Immutep Limited’s soft tissue sarcoma data may now define eftilagimod alfa’s future. Find out why this could reshape its oncology strategy.
AACR 2026: Precision Biologics says it found a new weak spot in AML for CAR-NK therapy
Precision Biologics has revealed a new AML CAR-NK target at AACR 2026. Read why truncated O-glycans could matter for future leukemia therapy.